Inspection Record

VAKOS XT a.s. — EU GMP NCR (EudraGMDP) Findings

EMA (Europe)Inspected 2019-11-05Published 2019-11-22 1 findingsComplaint and recall handling

View the regulator's official source The source document is always the basis for judgement.

Findings

1Complaint and recall handling

Totally 25 deficiencies were found, 1 was classified as critical, 17 as major. Most of deficiencies was found on adjacent manufacturing site but some of them were common. 2 major deficiencies were found in the Quality Management - system of deviations and change control were not established. Other major deficiencies cover requirements on premises and equipment, e.g. storage rooms are not cleaned properly. Action taken/proposed by the NCA: Suspension of the manufacturing authorisation No. sukls78312/2017 in Full Withdrawal, of current valid GMP certificate No. sukls426470/2018 GMP certificates invalidated Recall of batches already released A recall of medicinal products should be evaluated by involved NCAs following the assessment.

About this record

Extracted automatically from the document EMA (Europe) published on 2019-11-22. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

VAKOS XT a.s. company profile — full history EMA (Europe) documents, 2019 Go to Findings search